Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Belite Bio Inc ADR (BLTE)

Belite Bio Inc ADR (BLTE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit GlobeNewswire - Mon Apr 27, 7:00AM CDT

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc. (NASDAQ: BLTE), (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing...

BLTE : 154.88 (-0.72%)
Belite Bio to Participate in Four Upcoming Investor Conferences GlobeNewswire - Thu Apr 23, 7:00AM CDT

SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 154.88 (-0.72%)
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease GlobeNewswire - Tue Apr 21, 3:00PM CDT

Belite expects to complete the new drug application submission in the second quarter of 2026 Rolling submission initiated under Breakthrough Therapy Designation SAN DIEGO, April 21, 2026 (GLOBE...

BLTE : 154.88 (-0.72%)
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website GlobeNewswire - Tue Mar 31, 7:00AM CDT

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that...

BLTE : 154.88 (-0.72%)
Belite Bio to Participate in the Leerink Global Healthcare Conference GlobeNewswire - Mon Mar 2, 7:00AM CST

SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc  (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 154.88 (-0.72%)
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update GlobeNewswire - Mon Mar 2, 5:00AM CST

Following positive topline results from the pivotal, global Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), the Company is on track to submit a New Drug Application...

BLTE : 154.88 (-0.72%)
Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Mon Feb 23, 7:00AM CST

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases...

BLTE : 154.88 (-0.72%)
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO) GlobeNewswire - Thu Jan 29, 7:00AM CST

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 154.88 (-0.72%)
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1) GlobeNewswire - Tue Jan 27, 7:00AM CST

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint in the pivotal, global Phase 3 DRAGON trial with 36% reduction in lesion...

BLTE : 154.88 (-0.72%)
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares GlobeNewswire - Mon Dec 1, 2025

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 154.88 (-0.72%)

Barchart Exclusives

JPMorgan vs. Bank of America: How the 2 Dividend-Paying Bank Stocks Stack Up in 2026 Barchart - Fri May 8, 6:00PM CDT
JPMorgan dominates on scale and profits, while Bank of America wins on value and yield. Here's which big bank stock deserves your money in 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.